IPO update: PolyPid files for $24M IPO; DBV sets terms for $98M IPO; Atara prices below the range;

@FierceBiotech: InterMune and Boehringer win tandem FDA nods for 'breakthrough' lung drugs. News | Follow @FierceBiotech

@JohnCFierce: Well that tax inversion business was a lot of fun--I wonder what the next big biopharma M&A trend will be. More | Follow @JohnCFierce

@DamianFierce: IPF drugs from $ITMN and Boehringer Ingelheim win FDA approvals at the same time. | Follow @DamianFierce

@EmilyMFierce: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More from FierceVaccines | Follow @EmilyMFierce

> The Israeli biotech PolyPid, which is developing new drug delivery tech, has filed for a $24 million IPO. SEC filing

> France's DBV Technologies, which is working on a new therapy for food allergies, set its terms for a $98 million IPO. Report

> Atara Biotherapeutics took a haircut on its IPO, pricing shares at $11, well below the range of $14 to $16. The share price quickly slipped once trading began. Story

> Toronto-based Highland Therapeutics has raised $25 million. Release

Medical Device News

@FierceMedDev: Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Advisory board recommends that Arkansas Medicaid cut restrictions on $VRTX's cystic-fibrosis drug Kalydeco. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. FierceDrugDelivery article | Follow @MichaelGFierce

> Agilent axes 300 employees to focus on applied markets and diagnostics businesses. More

> Wearable sensor shown effective in preventing bedsores. Story

> Medtronic scores victory in ongoing patent war with Mirowski. Article

Pharma News

@FiercePharma: Top-read in FiercePharmaMarketing Weds: World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Article | Follow @FiercePharma

@EricPFierce: Remember when FDA asked heparin makers to test APIs for OCSC? This warning letter to a Chinese co. is why. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Have you seen FP's latest report? The top 10 most expensive drugs of 2013. Feature | Follow @CarlyHFierce

> AbbVie calls it quits on $55B Shire takeover. News

> Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%. Article

Vaccines News

> Sanofi inks pact with Immune Design to boost herpes vax effort. Story

> Bexsero could be cost-effective for England, model says--but not at Novartis' price. Report

> Sanofi, Selecta join hands in diabetes vaccine push. Article

> NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More

> Sanofi takes rotavirus vax into Phase III with eye on Indian market. Story

Pharma Manufacturing News

> FDA bans maker of suspect Chinese heparin. More

> Court orders Indian drugmaker to destroy $11M worth of unapproved drugs. Story

> FDA cites animal drug compounder for selling copies of Novartis' Capstar. Item

> Italy's Cosmos to build manufacturing plant in Ireland. News

> Abbott opens third nutrition plant this year. Article

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.